ProPhase Labs, Inc.
PRPHNASDAQHealthcare● Active
$0.10
$-0.01(-9.09%)
Market Cap$473701
P/E Ratio—
52W High$6.7
52W Low$0.07
ProPhase Labs, Inc. (PRPH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PRPH · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Jun 4, 2026EPS Actual
-$0.87
Est. -$1.20 · +27.5%
Revenue
$0.00B
Est. $0.01B · -91.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Jun 4, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
PRPH reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Jun 8, 2026 | — | — | — | — | — | — |
| ▲ Q2 FY2026 | Jun 4, 2026 | -$1.20 | -$0.87 | +27.5% | $0.00B | $0.01B | -91.9% |
| ▼ Q4 FY2025 | Nov 19, 2025 | -$1.10 | -$1.60 | -45.5% | $0.00B | $0.01B | -84.5% |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.15 | -$0.11 | +26.7% | $0.00B | $0.01B | -78.1% |
| ▲ Q2 FY2025 | May 20, 2025 | -$0.18 | -$0.12 | +33.3% | $0.00B | $0.00B | -59.7% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.24 | -$0.51 | -112.5% | $-0.00B | $0.00B | -201.4% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.31 | -$0.35 | -12.9% | $0.00B | $0.01B | -46.5% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -$0.08 | -$0.33 | -312.5% | $0.00B | $0.01B | -77.8% |
Q2 FY2026
Jun 8, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 4, 2026Beat
EPS Actual
-$0.87
EPS Est.
-$1.20
EPS Surpr.
+27.5%
Revenue
$0.00B
Q4 FY2025
Nov 19, 2025Miss
EPS Actual
-$1.60
EPS Est.
-$1.10
EPS Surpr.
-45.5%
Revenue
$0.00B
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.15
EPS Surpr.
+26.7%
Revenue
$0.00B
Q2 FY2025
May 20, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.18
EPS Surpr.
+33.3%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.51
EPS Est.
-$0.24
EPS Surpr.
-112.5%
Revenue
$-0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.35
EPS Est.
-$0.31
EPS Surpr.
-12.9%
Revenue
$0.00B
Q3 FY2024
Aug 14, 2024Miss
EPS Actual
-$0.33
EPS Est.
-$0.08
EPS Surpr.
-312.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-1.20 | $-1.20 | $-1.20 | 1 |
| Q3 FY2025 | $-1.10 | $-1.10 | $-1.10 | 1 |
| Q2 FY2025 | $-1.50 | $-1.50 | $-1.50 | 1 |
| Q1 FY2025 | $-1.80 | $-1.80 | $-1.80 | 1 |
| Q4 FY2024 | $-3.10 | $-3.10 | $-3.10 | 1 |
| Q3 FY2024 | $-0.80 | $-0.80 | $-0.80 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Jun 4, 2026 | +27.5% | $0.14 | $0.13 | -7.82% |
| ▼ Q4 FY2025 | Nov 19, 2025 | -45.5% | $2.58 | $2.34 | -9.30% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +26.7% | $3.54 | $3.27 | -7.63% |
| ▲ Q2 FY2025 | May 20, 2025 | +33.3% | $3.21 | $3.28 | +2.18% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -112.5% | $4.40 | $4.04 | -8.18% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -12.9% | $7.38 | $7.70 | +4.34% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -312.5% | $12.40 | $12.50 | +0.81% |
| ▲ Q2 FY2024 | May 9, 2024 | +75.0% | $27.00 | $24.60 | -8.89% |
Q2 FY2026-7.82%
Report Date
Jun 4, 2026
EPS Beat/Miss
+27.5%
Price Before
$0.14
Price After
$0.13
Q4 FY2025-9.30%
Report Date
Nov 19, 2025
EPS Beat/Miss
-45.5%
Price Before
$2.58
Price After
$2.34
Q3 FY2025-7.63%
Report Date
Aug 13, 2025
EPS Beat/Miss
+26.7%
Price Before
$3.54
Price After
$3.27
Q2 FY2025+2.18%
Report Date
May 20, 2025
EPS Beat/Miss
+33.3%
Price Before
$3.21
Price After
$3.28
Q1 FY2025-8.18%
Report Date
Mar 31, 2025
EPS Beat/Miss
-112.5%
Price Before
$4.40
Price After
$4.04
Q4 FY2024+4.34%
Report Date
Nov 13, 2024
EPS Beat/Miss
-12.9%
Price Before
$7.38
Price After
$7.70
Q3 FY2024+0.81%
Report Date
Aug 14, 2024
EPS Beat/Miss
-312.5%
Price Before
$12.40
Price After
$12.50
Q2 FY2024-8.89%
Report Date
May 9, 2024
EPS Beat/Miss
+75.0%
Price Before
$27.00
Price After
$24.60
Avg Beat Reaction-5.54%
Avg Miss Reaction-3.08%
Beat Rate4 / 8 quarters
Largest Move-9.30% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PRPH ends December
ProPhase Labs, Inc. (PRPH) most recently reported earnings on June 4, 2026 for Q2 FY2026, posting EPS of $-0.87 — beating the analyst consensus of $-1.20 by +27.5%. The next PRPH earnings date is expected around September 1, 2026.
Each quarter, investors track PRPH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PRPH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PRPH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PRPH earnings · 5 questionsProPhase Labs, Inc.'s next earnings report is expected around September 1, 2026. PRPH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PRPH historically reports after market close (AMC).
PRPH earnings datewhen is PRPH earningsPRPH next earnings datewhen does PRPH report earningsPRPH earnings calendar
▸ Source: FMP · ProPhase Labs, Inc. SEC filings · US GAAP · ProPhase Labs, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026